This study checks how **Enobosarm**, a drug, affects body weight when used with a **GLP-1 receptor agonist** like semaglutide for weight loss. GLP-1 receptor agonists are medicines that help control blood sugar and reduce weight. Participants will be divided into two groups: one group will receive semaglutide and Enobosarm, while the other group will receive semaglutide and a placebo (a pill with no medicine). The study lasts for 68 weeks, during which participants will take semaglutide injections and either Enobosarm or placebo pills. The main goal is to see how much body weight changes by the end. A safety check will occur about 30 days after the study ends. **Key Points:** - The study lasts **68 weeks** (476 days). - Participants need to be **65 years or older**. - Safety follow-up visit 30 days after the last dose. Participants should be able to swallow pills, have a BMI (Body Mass Index) of 35 or higher, and be willing to take part in all study activities, like physical fitness tests. Those with certain medical conditions or allergies to the study drugs might not be eligible.